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Background: Subcutaneous (SQ) infusion of Cenderitide (C), a chimeric natriuretic peptide (NP) with agonism for NP receptors A and B, is being 
developed as a maintenance therapy to improve clinical outcomes in post-acute heart failure (HF) patients.
Methods: This multi-centered Phase 1 dose escalating study evaluated the pharmacokinetic (PK) and pharmacodynamic responses to various SQ 
boluses and infusion regimens in HF patients. Systolic HF patients with an ejection fraction ≤ 40%, on stable HF medications, and systolic blood 
pressure (SBP) ≥ 105 mmHg were enrolled. Subjects were initially dosed with SQ boluses of C to evaluate bioavailability. Based on these results, 
additional cohorts were randomized to 24-hour continuous subcutaneous infusions of C or matching placebo using a Medtronic SQ pump to achieve 
targeted steady-state plasma levels of C. Direct glomerular filtration rate (GFR), renal biomarkers, and urine output (UO) were measured in the SQ 
infusion cohorts.
Results: 58 subjects were dosed (45 with C and 13 with placebo). The infusions were well tolerated. The results of escalating SQ boluses of C in 
12 subjects confirmed good bioavailability and were used to determine the doses for the 24-h SQ infusions. SQ infusion regimens were 18 μg/hr 
(n=12), 24 μg/hr (n=10), 36 μg/hr (n=2), and a weight-based dosing regimen (n=9), or matching placebo (n=13). The demographics of the subjects 
receiving placebo and C were similar. Targeted plasma levels of C were achieved. A dose-dependent reduction in SBP occurred. The mean maximum 
SBP reductions for the 18 μg/hr, 24 μg/hr, 36 μg/hr, weight-based, and placebo of -16±12, -22±8, -28±1 -19±7, and -12±10 mmHg, respectively. 
The PK variability of the weight-based cohort was less relative to the fixed dose regimens. No difference in GFR, creatinine, cystatin-C or UO between 
the placebo and the C dosed groups was detected.
Conclusion: SQ infusion of Cenderitide was well-tolerated, achieved and maintained targeted plasma levels, and produced a consistent dose-
dependent reduction in SBP. This study supports a novel strategy for chronic administration with cenderitide for human HF.
